Ligand Pharmaceuticals Incorporated (LGND)
Dopo ore:
| Chiusura precedente | 87,21 |
| Aperto | 86,66 |
| Denaro | 0,00 x 1300 |
| Lettera | 0,00 x 1000 |
| Min-Max giorno | 85,53 - 88,51 |
| Intervallo di 52 settimane | 72,57 - 169,98 |
| Volume | |
| Media Volume | 158.288 |
| Capitalizzazione | 1,492B |
| Beta (5 anni mensile) | 1,22 |
| Rapporto PE (ttm) | 67,54 |
| EPS (ttm) | 1,31 |
| Prossima data utili | 27 lug 2022 - 01 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | 02 lug 2010 |
| Stima target 1A | 182,50 |
- GlobeNewswire
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
Key Opinion Leader (KOL) webinar scheduled for Wednesday, June 15, at 10:00 a.m. EDTCOLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will host a virtual update on its ELAINE Phase 2 clinical programs on Wednesday, June 15 at 10:00 a.m. EDT. The event will feature presentations from Key
- GlobeNewswire
Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 3-7 at McCormick Place in Chicago and online. Details of the presentations are as follows: Title: Open-lab
- GlobeNewswire
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutationCOLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboratio
